Phil Miller, product director at Thomson Reuters, said: "High failure rates continue to be of great concern to the industry and this is compounded by the decrease in NMEs. The strategy of big pharma to in-license more drugs for development does not appear to be paying off at present. An earlier focus on clearing out weak drug candidates will be instrumental to successfully progressing drugs to market."
In addition, despite the overall decrease in the number of new drugs entering each stage of clinical trials, Anti-Cancer is one of only two therapeutic areas to see positive growth in the number of drugs being developed for launch.
The information published in the Factbook is based on primary sources covering major pharmaceutical companies which account for approximately 80 percent of the industry's global R&D expenditure.
CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. For almost 15 years, CMR International has worked with the leading global pharmaceutical companies to assess R&D productivity and provide insights into industry trends in order to strengthen planning and effectiveness of R&D. Since 2003, CMR International has published the pharmaceutical R&D Factbook, an annual report for the pharmaceutical R&D sector providing a reliable source of key reference metrics.
*Source IMS Health
For further information, please go to: http://cmr.thomsonreuters.com/services/factbook.
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets,
|SOURCE Thomson Reuters|
Copyright©2010 PR Newswire.
All rights reserved